Stock comparison
Bio-Rad Laboratories
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIO
Bio-Rad Laboratories
Market cap
$7.78B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIO | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 72B | LLY |
| Benjamin Graham | 48D | 86A | LLY |
| Philip Fisher | 30F | 86A | LLY |
| Peter Lynch | 10F | 74B | LLY |
| Joel Greenblatt | 42D | 78C | LLY |
| Charlie Munger | 34F | 85A | LLY |
| Terry Smith | 26F | 77C | LLY |
Side-by-side metrics
| Metric | BIO | LLY |
|---|---|---|
| Market cap | $7.78B | $1T |
| P/E (TTM) | 39.5x | 36.6x |
| EV/EBIT | 28.0x | 34.1x |
| ROIC (TTM) | 1.95% | 32.06% |
| Gross margin | 51.87% | 83.51% |
| Net margin | 6.52% | 34.98% |
| Revenue CAGR 5y | -3.04% | 23.17% |
| EPS CAGR 5y | -33.51% | 40.81% |
| Debt / Equity | 0.2x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
- Debt / Equity0.2xvs 1.4x+86%
- EV/EBIT28.0xvs 34.1x+18%
LLY leads on
- EPS CAGR 5y40.81%vs -33.51%+182%
- Revenue CAGR 5y23.17%vs -3.04%+113%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $7.78B+99%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.